Reprogramming Human Melanocytes and Melanoma Cells with Yamanaka Factors
The generation of induced pluripotent stem (iPS) cells from somatic cells showed that cell fate could be
manipulated by simply introducing a few transcription factors. The differentiation potential of iPS cells has
uncovered a wide range of potential applications, including disease modeling, drug screening and regenerative
therapy. In this study, we aimed to induce reprogramming of human melanocytes and melanoma cell lines
via Sendai viral vectors encoding Yamanaka factors. Following transfection, pluripotent stem cell colonies
have emerged in the melanocyte cultures, as evident by phase-contrast and fluorescence microscopy images.
However, only cell clusters which were not positive for pluripotency markers were obtained in the melanoma
cell cultures. This proved that there are differences between healthy and cancer cell reprogramming. Basal
gene expression of Yamanaka factors, pluripotency markers and tumor-suppressor genes have been identified
in order to understand the different responses for cell reprogramming in melanocytes and cancer cell lines.
Future studies that will allow efficient reprogramming of cancer cells can improve our knowledge about cancer
biology and therapy
___
- K. Takahashi, S. Yamanaka, Induction of pluripotent
stem cells from mouse embryonic and adult fibroblast
cultures by defined factors, Cell, 126 (2006) 663-76.
- I.H. Park, N. Arora, H. Huo, N. Maherali, T. Ahfeldt, A.
Shimamura, M.W. Lensch, C. Cowan, K. Hochedlinger,
G.Q. Daley, Disease-specific induced pluripotent stem
cells, Cell, 134 (2008) 877-86.
- F.T. Merkle, K. Eggan, Modeling human disease with
pluripotent stem cells: from genome association to
function, Cell. Stem Cell, 12 (2013) 656-68.
- J. Sng, T. Lufkin, Emerging stem cell therapies:
treatment, safety, and biology, Stem Cells Int., 2012
(2012) 521343.
- M.A. Dawson, T. Kouzarides, Cancer epigenetics: from
mechanism to therapy, Cell, 150 (2013) 12-27.
- S.B. Baylin, J.E. Ohm, Epigenetic gene silencing in
cancer - a mechanism for early oncogenic pathway
addiction?, Nat. Rev. Cancer, 6 (2006) 107-116.
- A.P. Feinberg, B. Tycko, The history of cancer
epigenetics, Nat. Rev. Cancer, 4 (2004) 143-153.
- P.A. Jones, S.B. Baylin, The fundamental role of
epigenetic events in cancer, Nat. Rev. Genet., 3
(2002) 415-428.
- C.A. Gifford, Michael J. Ziller, H. Gu, C. Trapnell, J.
Donaghey, A. Tsankov, A.K. Shalek, D.R. Kelley, A.A.
Shishkin, R. Issner, X. Zhang, M. Coyne, J.L. Fostel, L.
Holmes, J. Meldrim, M. Guttman, C. Epstein, H. Park,
O. Kohlbacher, J. Rinn, A. Gnirke, E.S. Lander, B.E.
Bernstein, A. Meissner, Transcriptional and epigenetic
dynamics during specification of human embryonic
stem cells, Cell, 153 (2013) 1149-1163.
- W. Xie, M.D. Schultz, R. Lister, Z. Hou, N. Rajagopal, P.
Ray, J. W. Whitaker, S. Tian, R.D. Hawkins, D. Leung,
H. Yang, T. Wang, Ah Y. Lee, S.A. Swanson, J. Zhang,
Y. Zhu, A. Kim, J.R. Nery, Mark A. Urich, S. Kuan, C.-a.
Yen, S. Klugman, P. Yu, K. Suknuntha, N.E. Propson, H.
Chen, L.E. Edsall, U. Wagner, Y. Li, Z. Ye, A. Kulkarni,
Z. Xuan, W.-Y. Chung, N.C. Chi, J.E. AntosiewiczBourget,
I. Slukvin, R. Stewart, M.Q. Zhang, W. Wang,
J.A. Thomson, J.R. Ecker, B. Ren, Epigenomic analysis
of multilineage differentiation of human embryonic
stem cells, Cell, 153 (2013) 1134-1148.
- J. Zhu, M. Adli, J.Y. Zou, G. Verstappen, M. Coyne, X.
Zhang, T. Durham, M. Miri, V. Deshpande, P.L. De Jager,
D.A. Bennett, J.A. Houmard, D.M. Muoio, T.T. Onder,
R. Camahort, C.A. Cowan, A. Meissner, C.B. Epstein,
N. Shoresh B.E. Bernstein, Genome-wide chromatin
state transitions associated with developmental and
environmental Cues, Cell, 152 (2013) 642-654.
- B. Papp, K. Plath, Epigenetics of reprogramming to
induced pluripotency, Cell, 152 (2013) 1324-43.
- R.P. Koche, Z.D. Smith, M. Adli, H. Gu, M. Ku, A. Gnirke,
B.E. Bernstein, A. Meissner, Reprogramming factor
expression initiates widespread targeted chromatin
remodeling, Cell. Stem. Cell, 8 (2013) 96-105.
- A. Yilmazer, I. de Lázaro, H. Taheri, Reprogramming
cancer cells: a novel approach for cancer therapy or
a tool for disease-modeling?, Cancer Letters, 369
(2015) 1-8.